Diurnal Group PLC Posting of Annual Report and AGM Notice (5503B)

TIDMDNL

RNS Number : 5503B

Diurnal Group PLC

08 October 2020

8 October 2020

Diurnal Group plc

("Diurnal" or the "Company")

Posting of Annual Report and AGM Notice

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that its Annual Report and Accounts for the year ending 30 June 2020, together with the Notice of Annual General Meeting (AGM), have today been posted to shareholders.

The documents are being made available on the investor relations section of the Company's website, www.diurnal.co.uk .

The Company's AGM will be held at 11:00 GMT at the Company's London office at Regus Woburn Place, 16 Upper Woburn Place, London, WC1H 0BS on Tuesday 20 November 2020. Due to the ongoing COVID-19 pandemic and in line with UK Government advice, the Board has decided to run the 2020 AGM as a closed meeting and shareholders will not be able to attend.

In the light of these measures, the Board strongly encourages shareholders to vote by proxy in accordance with the instructions in the Notice of AGM. Shareholders can submit questions to the Company ahead of the AGM as per instructions included within the Notice of AGM.

 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                   [phone] 
 Diurnal Group plc                                  1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser    [phone] 
  and Sole Broker)                                  2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: Rupert Dearden 
 
                                                   [phone] 
 FTI Consulting (Media and Investor Relations)      1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOABXBDGLDGDGGI

(END) Dow Jones Newswires

October 08, 2020 09:28 ET (13:28 GMT)